ZA933786B - Substituted phenylimidazolidines their preparationprocess their use as medicaments and the pharmace utical compositions containing them - Google Patents

Substituted phenylimidazolidines their preparationprocess their use as medicaments and the pharmace utical compositions containing them

Info

Publication number
ZA933786B
ZA933786B ZA933786A ZA933786A ZA933786B ZA 933786 B ZA933786 B ZA 933786B ZA 933786 A ZA933786 A ZA 933786A ZA 933786 A ZA933786 A ZA 933786A ZA 933786 B ZA933786 B ZA 933786B
Authority
ZA
South Africa
Prior art keywords
medicaments
halogen
preparationprocess
compositions containing
image
Prior art date
Application number
ZA933786A
Other languages
English (en)
Inventor
Martine Gaillard-Kelly
Francois Goubet
Daniel Philibert
Jean-Georges Teutsch
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of ZA933786B publication Critical patent/ZA933786B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA933786A 1992-07-08 1993-05-28 Substituted phenylimidazolidines their preparationprocess their use as medicaments and the pharmace utical compositions containing them ZA933786B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR929208431A FR2693461B1 (fr) 1992-07-08 1992-07-08 Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.

Publications (1)

Publication Number Publication Date
ZA933786B true ZA933786B (en) 1994-05-30

Family

ID=9431679

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA933786A ZA933786B (en) 1992-07-08 1993-05-28 Substituted phenylimidazolidines their preparationprocess their use as medicaments and the pharmace utical compositions containing them

Country Status (17)

Country Link
EP (1) EP0580459B1 (ja)
JP (1) JP3845455B2 (ja)
KR (1) KR100294383B1 (ja)
CN (1) CN1044234C (ja)
AT (1) ATE200077T1 (ja)
AU (1) AU670942B2 (ja)
CA (1) CA2097248A1 (ja)
DE (1) DE69330058T2 (ja)
DK (1) DK0580459T3 (ja)
ES (1) ES2155067T3 (ja)
FR (1) FR2693461B1 (ja)
GR (1) GR3035768T3 (ja)
HU (1) HUT64527A (ja)
PT (1) PT580459E (ja)
RU (1) RU2116298C1 (ja)
UA (1) UA34428C2 (ja)
ZA (1) ZA933786B (ja)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
AU726572B2 (en) * 1994-02-16 2000-11-09 Aventis Pharma S.A. Cosmetics or pharmaceutical compositions consisting of liposomes
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
FR2742749B1 (fr) * 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
WO2000024366A1 (de) * 1998-10-23 2000-05-04 Aventis Pharma Deutschland Gmbh Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen
JP4621335B2 (ja) 2000-06-28 2011-01-26 セイコーエプソン株式会社 情報端末用プリンタユニット
AU2002360932A1 (en) * 2001-11-23 2003-06-10 Schering Aktiengesellschaft Piperazine derivatives destabilising androgen receptors
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
DE10218963A1 (de) * 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
US20060025589A1 (en) * 2002-10-01 2006-02-02 Jean Binet 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2845383B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
DE10322108B4 (de) * 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
US7271188B2 (en) 2003-06-12 2007-09-18 Chugai Seikayu Kabushiki Kaisha Imidazolidine derivatives
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en) 2004-02-24 2005-10-27 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
TW200612920A (en) * 2004-08-03 2006-05-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivatives
CN101048381A (zh) * 2004-09-09 2007-10-03 中外制药株式会社 新型四氢咪唑衍生物及其用途
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
ES2314922T3 (es) * 2005-05-13 2009-03-16 Eli Lilly And Company N-arilpirrolidinas sustituidas como moduladores selectivos del receptor de androgenos.
AU2013203255C1 (en) * 2005-05-13 2017-01-19 The Regents Of The University Of California Diarylthiohydantoin compounds
RS52274B2 (sr) * 2005-05-13 2018-05-31 Univ California Jedinjenje diarilhidantoina
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
DK2656842T3 (en) 2006-03-27 2016-11-07 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
SG10201408699TA (en) 2006-03-29 2015-02-27 Univ California Diarylthiohydantoin compounds
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
EP2242747A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
CN102112440A (zh) 2008-05-30 2011-06-29 武田药品工业株式会社 杂环化合物
WO2010069519A1 (en) 2008-12-18 2010-06-24 Merz Pharma Gmbh & Co. Kgaa Topical compositions comprising at least one active ingredient poorly soluble in water and biopolymers such as hyaluronic acid with a pka-value between 5-7
KR20110113755A (ko) 2009-02-10 2011-10-18 아스트라제네카 아베 트리아졸로 〔4,3-ｂ〕 피리다진 유도체 및 전립샘암에 대한 이의 용도
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954316B1 (fr) 2009-12-23 2014-01-03 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954315B1 (fr) 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
MX355915B (es) 2010-02-16 2018-05-04 Aragon Pharmaceuticals Inc Moduladores del receptor de androgenos y usos de los mismos.
HUE055051T2 (hu) * 2010-02-24 2021-10-28 Medivation Prostate Therapeutics Llc Eljárás diaril-tiohidantoin és diaril-hidantoin vegyületek szintézisére
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
BR112013007685B1 (pt) 2010-09-28 2021-11-09 Radius Pharmaceuticals, Inc Compostos moduladores de receptor andrógeno seletivos, composição farmacêutica compreendendo os referidos compostos, método de identificação de um composto capaz de modular um receptor andrógeno, usos de um composto ou da composição e processo para a preparação de um composto
EA202190820A1 (ru) 2012-09-26 2021-10-29 Арагон Фармасьютикалз, Инк. Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP4035664A3 (en) 2014-03-28 2022-11-30 Duke University Treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN103965112A (zh) * 2014-05-13 2014-08-06 上海孚一生物科技有限公司 一种具有抗雄激素活性的化合物、制备方法及其应用
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
RU2769527C2 (ru) 2016-06-22 2022-04-01 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
KR102322802B1 (ko) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
WO2019078920A1 (en) 2017-10-16 2019-04-25 Aragon Pharmaceuticals, Inc. ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4916937B1 (ja) * 1970-01-21 1974-04-25
US3823240A (en) * 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
US3923994A (en) * 1973-07-13 1975-12-02 Smithkline Corp Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
DE2933917A1 (de) * 1979-08-22 1981-03-26 Basf Ag, 67063 Ludwigshafen 5-imino-imidazolidin-2-one und diese enthaltende herbizide.
US4753957A (en) * 1981-09-28 1988-06-28 Rohm And Haas Company Substituted 2,4-imidazolidinediones and fungicidal compositions
EP0091596B1 (de) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
US4473393A (en) * 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
KR940005582A (ko) 1994-03-21
JPH0673017A (ja) 1994-03-15
JP3845455B2 (ja) 2006-11-15
PT580459E (pt) 2001-07-31
UA34428C2 (uk) 2001-03-15
EP0580459A1 (fr) 1994-01-26
EP0580459B1 (fr) 2001-03-28
CA2097248A1 (fr) 1994-01-09
ES2155067T3 (es) 2001-05-01
FR2693461B1 (fr) 1994-09-02
CN1081182A (zh) 1994-01-26
RU2116298C1 (ru) 1998-07-27
KR100294383B1 (ko) 2001-09-17
AU3987693A (en) 1994-01-13
FR2693461A1 (fr) 1994-01-14
ATE200077T1 (de) 2001-04-15
CN1044234C (zh) 1999-07-21
HUT64527A (en) 1994-01-28
GR3035768T3 (en) 2001-07-31
DE69330058T2 (de) 2001-09-06
DK0580459T3 (da) 2001-06-11
AU670942B2 (en) 1996-08-08
HU9301585D0 (en) 1993-09-28
DE69330058D1 (de) 2001-05-03

Similar Documents

Publication Publication Date Title
ZA933786B (en) Substituted phenylimidazolidines their preparationprocess their use as medicaments and the pharmace utical compositions containing them
ZA9290B (en) Phenylimidazolidines,process for their preparation,their use as medicaments and pharmaceutical compositions containing them
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
GB9514473D0 (en) Chemical compounds
HK1041875A1 (en) Amide derivatives
IL110031A0 (en) Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them
TR200000535T2 (tr) NOS önleyicileri olarak ekli halka ikameleri içeren 2-aminopiridinler.
MX9700340A (es) Agentes anti-helicobacter derivados sulfonamida de azolonas.
HUP0301631A2 (hu) VIIa faktort gátló (tio)karbamid-származékok, azokat tartalmazó gyógyszerkészítmények, elżállításuk és alkalmazásuk
DK0858804T3 (da) Anvendelse af rifaximin og farmaceutiske præparater indeholdende dette i behandlingen af diarré forårsaget af cryptosporidiosis
ZA200110540B (en) Novel diphenyl-piperidine derivate.
IL131407A0 (en) Tetrahydropyrido compounds medicaments containing the same and the use thereof
BR9507289A (pt) Derivados de éster e carbamato de azolonas com atividade anti-heli-cobacteriana
TW269680B (ja)
IL112344A (en) Pharmaceutical compositions comprising 7, 9, 9-trisubstituted- 3-benzoyl-3, 7-diazabicyclo £3.3.1| nonanes for the treatment of cardiac arrhythmias
ES8604843A1 (es) Un metodo para la preparacion de un derivado de acetileno
EP0785193A4 (en) ARYLTHIADIAZOLE DERIVATIVES AND ANTIVIRAL PRODUCTS CONTAINING THEM
MX9703288A (es) Oxazolil- y tiazolilimidazo-benzo- y tienodiacepinas y su uso como medicamentos.
PL336239A1 (en) Sulphonyloxadiazolones and their application as microbicides
MX9605143A (es) Heterociclibenzonitrilos.